Asset Publisher

< Back to Final Medical Policies page

Final Policies - Laboratory

Policy # Policy Title Print View
MP-062 High Sensitivity C-Reactive Protein
MP-063 Fetal Fibronectin Enzyme Immunoassay
MP-071 Allergy Testing
MP-096 Antiprothrombin Antibody
MP-142 B-Natriuretic Peptide
MP-155 Measurement of Lipoprotein-Associated Phospholipase A2 in the Assessment of Cardiovascular Risk
MP-165 Antigen Leukocyte Antibody Test
MP-195 Serum Tumor Markers for Breast and Gastrointestinal Malignancies
MP-196 End-Tidal Carbon Monoxide Measurement (ETCOc)
MP-200 Evaluation of Biomarkers for Alzheimer Disease
MP-239 Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
MP-264 HIV Genotyping and Phenotyping
MP-285 Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease
MP-322 Laboratory Testing for HIV Tropism
MP-341 Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
MP-353 Anti-CCP Testing for Rheumatoid Arthritis
MP-378 Intracellular Micronutrient Analysis
MP-393 Bone Turnover Markers for the Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover
MP-407 Fecal Analysis in the Diagnosis of Intestinal Dysbiosis
MP-426 Multi-marker Serum-Testing Related to Ovarian Cancer
MP-428 Systems Pathology in Prostate Cancer
MP-445 Serum Biomarker Human Epididymis Protein 4 (HE4)
MP-448 Serum Holotranscobalamin as a Marker of Vitamin B12 (Cobalamin) Status
MP-472 Fecal Calprotectin Testing
MP-510 Measurement of Serum Antibodies to Selected Biologic Agents
MP-545 Human Leukocyte Antigen (HLA) Testing for Celiac Disease
MP-548 Identification of Microorganisms Using Nucleic Acid Probes
MP-562 Multianalyte Assays With Algorithmic Analyses for Predicting Risk of Type 2 Diabetes
MP-563 Serum Biomarker Tests for Multiple Sclerosis
MP-564 Biomarker and Disease Activity Testing for Rheumatoid Arthritis
MP-565 Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases
MP-566 Drug Testing
MP-567 Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease
MP-570 Proteomic Testing for Systemic Therapy in Non-Small Cell Lung Cancer
MP-584 Fecal Microbiota Transplantation
MP-592 Laboratory Tests for Chronic Heart Failure and Heart Transplant Rejection
MP-613 Nutrient/Nutritional Panel Testing
MP-707 Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer
MP-711 Plasma-Based Proteomic Screening of Pulmonary Nodules
MP-732 Testing Serum Vitamin D Levels
MP-746 Maternal Serum Biomarkers for Prediction of Adverse Obstetric Outcomes
MP-758 Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis